DURECT Corp.

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company’s lead product candidate includes larsucosterol, an endogenous, orally bioavailable small molecule to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as for the treatment of patients with metabolic dysfunction-associated steatohepatitis. The company also offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; PERSERIS, an injectable suspension for the treatment of schizophrenia in adults; and Methydur to treat attention deficit hyperactivity disorder. It has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.